Compare ADMA Biologics Inc (ADMA) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs State Street Technology Select Sector SPDR ETF — how do they compare? ADMA Biologics Inc trades at $9.27 (market cap $2.13B), while State Street Technology Select Sector SPDR ETF trades at $181.26. The key difference: State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | XLK | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Sector/Thematic |
52-Week High | $20.38 | $198.21 |
52-Week Low | $7.60 | $127.49 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
XLK trades at $183.60, up 1.73% with a neutral technical signal. The ETF has gained 33% year-to-date, making it the top-performing sector SPDR in 2026. Recent news highlights strong tech sector inflows and investor rotation patterns. Technical indicators show mixed signals with RSI readings in neutral territory and key support at $182.
Outlook remains positive given strong sector performance, though risks include potential Fed policy shifts and tech sector volatility. The ETF's low expense ratio and concentrated tech exposure provide competitive advantages, but investors should monitor macroeconomic indicators that could impact tech valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
